DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Chemotherapy Induced Nausea and Vomiting (CINV) - Epidemiology Insights - 2023" report to their offering.
Chemotherapy-induced nausea and vomiting (CINV) are both severe side effects of cancer treatment. CINV is a condition which makes a patient uncomfortable and has to be dealt properly as many patients delay their chemotherapy cycles or even refuse further treatment due to fear from future nausea and vomiting. Also, due to nausea and vomiting induced by chemotherapy, patients can't get nutrition properly and lose their energy and may become weak which may hinder the further chemotherapy cycles as patient wouldn't be physically string to bear the chemotherapy side-effects.
According to research, the Incident cases Chemotherapy Induced Nausea and Vomiting (CINV) is increasing and is expected to be 279,634 by 2023.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house forecast model analysis by our team of industry experts.
Scope of the Report:
- The report will help in developing business strategies by understanding the trends shaping and driving the Chemotherapy Induced Nausea and Vomiting (CINV) market.
- Insightful review of the key market drivers and barriers.
- To understand the regulatory scenario in major markets.
The report covers the detailed historical and forecasted Chemotherapy
Induced Nausea and Vomiting (CINV) epidemiology cases covering United
States, Europe (Germany, Spain, Italy, France and United Kingdom) and
Japan from 2013-2023.
Key Topics Covered:
- Report Introduction
- Chemotherapy Induced Nausea and Vomiting (CINV)
- Types of CINV
- Risk Factors
- Pathophysiology of CINV
- Epidemiology and Patient Population
- Assumptions and Caveats
- Market Drivers
- Market Barriers
- Unmet Needs
For more information about this report visit http://www.researchandmarkets.com/research/qqlh2t/chemotherapy